Price$318.10-7.06 (-2.17%)
01:30 PM07:45 PM
News · 26 weeks52-58%
2026-04-192026-10-11
Mix3190d
- Other12(39%)
- SEC Filings8(26%)
- Insider8(26%)
- M&A2(6%)
- Dividends1(3%)
Latest news
25 items- PRLabcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthAcquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwideBURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health.Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology
- PRLabcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health TestFirst lab test offered in collaboration with Thrive GlobalCombines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habitsDelivers insights from five key cardiometabolic health indicators paired with educational content and recommended Thrive Microsteps®BURLINGTON, N.C., Oct. 13, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Thrive 5 Health Test, the first lab test offered in collaboration with Arianna Huffington's behavior change technology company, Thrive Global. Available through Labcorp OnDemand, the offer
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.A replay of the webcast will be available on the "News & Events" sec
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor DayReaffirms full-year 2026 guidanceProvides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scalePresents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deploymentBURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-depth review of its
- PRMoonwalk Biosciences Announces $70 Million Series B: NYSE Content UpdateNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Sept. 9, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on September 9thMoonwalk Bio says recent funding will advance RNAi development.The startup says its treatments have demonstrated reductions in body weight and fat mass while preserving lean muscle mass.Moonwalk's lead development candidate is expected to enter first-in-human clinical studies in late 2027.CEO Dr. Alex Aravanis will
- PRLabcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical TrialsAcquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continentsBURLINGTON, N.C., Sept. 8, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed. The acquisition enhances Labcorp's position as a leading independent central laboratory services provider by expanding its pr
- INSIDERSEC Form 4 filed by EVP, CIO & CTO Oyegunwa Akinbolade4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by EVP, COO Meltzer Jonathan C4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by EVP and President, Diagnostics Vaughn Bryan T4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Pres of BLS, CMO & CSO Caveney Brian J4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial ComplexityEnhanced digital experience designed to improve visibility, simplify workflows and support faster decision-makingBURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplifying workflows and helping sponsors and i
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare ConferenceBURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET. A live audio webcast of the fireside chat will be available via the Labcorp Investor Relations website at ir.labcorp.com and archived for replay for 180 days following the event.About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors
- PRLabcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care SettingsElecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's diseaseIntended for individuals 55 and older with signs, symptoms or complaints of cognitive declineBURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identif
- INSIDERDirector Anderson Kerrii B sold $954,060 worth of shares (3,000 units at $318.02) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 6,563 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community HealthCollaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support curren
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Host Investor Day on September 10, 2026BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang and other members of the executive leadership team will discuss the company's go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations will be followed by a Q&A session.A live webcast of the event will be available through the Labcorp Investor Relations website beg
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- INSIDERPresident & CEO Schechter Adam H sold $1,495,808 worth of shares (4,669 units at $320.37) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 102,565 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- PRLabcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced MelanomaLabcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapiesSupports access to targeted treatment options for the deadliest form of skin cancerBURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
- INSIDEREVP, Chief Marketing Officer Summy Amy B. sold $283,428 worth of shares (924 units at $306.74), decreasing direct ownership by 12% to 6,956 units (SEC Form 4)4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
LH FAQ
7 questionsWhat does Labcorp Holdings Inc. do?
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based...Where does LH stock trade?
Labcorp Holdings Inc. (LH) is listed on NYSE.What sector and industry is LH in?
Labcorp Holdings Inc. operates in the Health Care sector, Medical Specialities industry.Does LH pay a dividend?
LH's most recent ex-dividend date was 2026-08-28 with a cash dividend of $0.72 per share. No future ex-date is on file yet.What are analysts saying about LH?
Labcorp Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold on 2025-07-10.What companies are similar to LH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare LH side-by-side with any of them on Quantisnow.How can I track LH on Quantisnow?
Quantisnow aggregates Labcorp Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LH to receive live email and push alerts on every new disclosure.